“Buy online, pick up in store” was music to shoppers’ ears over the holidays, and the department store chain led the orchestra.
Amazon’s shares didn’t do much in 2019, but growth in Prime and control over its own deliveries could make the stock one to watch in 2020.
Party City is making efforts to mitigate a bad year, but it still may be too early to celebrate.
A plan to connect with consumers, smooth out the buying experience, and control inventory may bring the once-iconic brand back into the spotlight.
The children's apparel seller has had a market-beating 2019, but it's not too late for investors to add it to their portfolios.
With a newly approved drug and a candidate treatment that the FDA has given its “breakthrough” designation, there's good reason to expect revenue growth.
The “Oprah effect” sent Dr. Phil to stardom, but it won’t drive WW share recovery unless the company’s other efforts can lift sales and subscriptions.
H&M’s online makeover is on its way to transforming share performance.
After investors' lukewarm reaction to the company's fiscal second quarter results -- is now the time for investors to buy the stock?
As department stores struggle, off-price retailers like TJX and Ross may offer investors a stock bargain.
Stitch Fix’s plans to stick to online business and innovate are reasons to see the stock in a positive light.
A newly expanded free return program may help the retailer garner the last flurry of purchases to make it the shopping season’s star.
An FDA panel’s vote lifted Horizon’s shares, but a steady rally will depend on the FDA’s approval decision.
The clothier’s record revenue isn’t enough to please investors when it faces the same grim retail environment as its competitors.
Nike’s comments on direct-to-consumer business and digital efforts on Dec. 19 will set the tone for the stock’s year-end performance and beyond.
The FDA's approval of a second Duchenne muscular dystrophy drug brings Sarepta one step closer to market leadership.
Cosmetics growth is weak, but partnerships with celebrity Kylie Jenner may mean bright days ahead for Ulta and Coty.
Sanofi has the perfect gift for investors: Investment in its most promising businesses with plans to keep growing the dividend.
Target, already a Black Friday winner, could be a retail star of the season as it offers exclusive "Frozen 2" items in its new Disney shops.
Sanofi, with sales falling in its older businesses, boosts its higher-growth immuno-oncology business with the $2.5 billion purchase of Synthorx.